Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Nancy L. Bartlett, Brian A. Costello, Betsy R. LaPlant, Stephen M. Ansell, John G. Kuruvilla, Craig B. Reeder, Lim S. Thye, Daniel M. Anderson, Kilannin Krysiak, Cody Ramirez, Jing Qi, Barry A. Siegel, Malachi Griffith, Obi L. Griffith, Felicia Gomez, Todd A. Fehniger

Blood (2018) 131 (2): 182–190.

https://doi.org/10.1182/blood-2017-09-804641

Published: 2018

Includes: Supplemental data

Journal Articles

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Blood (2017) 130 (10): 1198–1204.

https://doi.org/10.1182/blood-2017-05-782961

Published: 2017

Includes: Supplemental data

Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Blood (2017) 129 (26): 3419–3427.

https://doi.org/10.1182/blood-2017-02-765685

Published: 2017

Includes: Supplemental data

Journal Articles

Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma

Francis K Buadi, MD, Morie A. Gertz, MD, Betsy R. Laplant, MS, Alese Halvorson, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, David Dingli, MD PhD FRCP, Prashant Kapoor, MD, Wilson I Gonsalves, MD, Teresa Miceli, RN, Eva Brandes, RN, Scott L Stafford, MD, James A Martenson, MD, William J Hogan, MBChB, Shaji K. Kumar, MD

Blood (2016) 128 (22): 2267.

https://doi.org/10.1182/blood.V128.22.2267.2267

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Ayed O. Ayed, MD, Levi Pederson, William R. Macon, MD, Betsy R. Laplant, MS, Craig B. Reeder, MD, James M. Foran, MD, Garth Nelson, Candido E. Rivera, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 5322.

https://doi.org/10.1182/blood.V128.22.5322.5322

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Ayed O. Ayed, MD, Annalisa Chiappella, MD, Grzegorz S. Nowakowski, MD, Federica Cavallo, MD, Angela Giovanna Congiu, MD, Gianluca Gaidano, MD PhD, Levi Pederson, Betsy R. Laplant, MS, William R. Macon, MD, Gerardo Musuraca, MD, Alessandro Re, MD, Michele Spina, Thomas E. Witzig, MD, Umberto Vitolo

Blood (2016) 128 (22): 3033.

https://doi.org/10.1182/blood.V128.22.3033.3033

Published: 2016

Journal Articles

Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, MD, Betsy R. Laplant, MS, Levi Pederson, Matthew J Maurer, MS, William R. Macon, MD, Rebecca L King, MD, James Storhoff, Shannon Dennis, Anita K. Gandhi, PhD, Anjan Thakurta, PhD, Patrick R. Hagner, Lisa Rimsza, MD, Thomas M. Habermann, James R Cerhan, MD PhD, Thomas E. Witzig, MD

Blood (2016) 128 (22): 3035.

https://doi.org/10.1182/blood.V128.22.3035.3035

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Blood (2016) 128 (22): 4392.

https://doi.org/10.1182/blood.V128.22.4392.4392

Published: 2016

Journal Articles

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Jun Yin, PhD, Betsy R. Laplant, MS, Geoffrey L. Uy, MD, Guido Marcucci, MD, William Blum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra Mandrekar, PhD

Blood (2016) 128 (22): 214.

https://doi.org/10.1182/blood.V128.22.214.214

Published: 2016

Journal Articles

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Blood (2016) 128 (20): 2415–2422.

https://doi.org/10.1182/blood-2016-05-717769

Published: 2016

Journal Articles

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

Patrick B. Johnston, MD PhD, Betsy R. Laplant, MS, Ellen D. McPhail, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Joseph P. Colgan, MD, Grzegorz S. Nowakowski, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD

Blood (2015) 126 (23): 813.

https://doi.org/10.1182/blood.V126.23.813.813

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood (2015) 126 (23): 3050.

https://doi.org/10.1182/blood.V126.23.3050.3050

Published: 2015

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

Blood (2014) 124 (21): 304.

https://doi.org/10.1182/blood.V124.21.304.304

Published: 2014

Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Blood (2014) 124 (21): 4780.

https://doi.org/10.1182/blood.V124.21.4780.4780

Published: 2014

Journal Articles

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Nancy L. Bartlett, MD, Betsy R. LaPlant, MS, Jing Qi, MD PhD, Stephen M. Ansell, MD PhD, John G. Kuruvilla, MD, Craig B. Reeder, MD, Lim S. Thye, MD, Daniel M. Anderson, MD MPH, Charles Erlichman, MD, Barry A. Siegel, MD

Blood (2014) 124 (21): 800.

https://doi.org/10.1182/blood.V124.21.800.800

Published: 2014

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia

Nandita Bose, PhD, Clive S. Zent, MD, Betsy R. LaPlant, MS, Nadine Ottoson, Steven Leonardo, PhD, George J Weiner, MD, Stephen M. Ansell, MD PhD

Blood (2014) 124 (21): 5662.

https://doi.org/10.1182/blood.V124.21.5662.5662

Published: 2014

Journal Articles

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Tait D. Shanafelt, MD, Betsy R. LaPlant, MS, Timothy G Call, MD, Daniel Nikcevich, MD PhD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Adam Pettinger, Daniel L. Van Dyke, PhD, Diane F. Jelinek, Curtis A. Hanson, MD, Neil E. Kay, MD

Blood (2014) 124 (21): 4673.

https://doi.org/10.1182/blood.V124.21.4673.4673

Published: 2014

NARROW

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only